Richard Schilsky to Neoplasms
This is a "connection" page, showing publications Richard Schilsky has written about Neoplasms.
Connection Strength
13.541
-
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2024 Apr; 8:e2300527.
Score: 0.336
-
Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar; 8:e2300615.
Score: 0.334
-
The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec; 20(6):699-707.
Score: 0.320
-
Beyond the COVID-19 Pandemic: Sustaining and Improving Equitable Cancer Care and Research. Cancer J. 2022 Mar-Apr 01; 28(2):105-106.
Score: 0.291
-
'Strategic' development of precision cancer medicine in the United States. Mol Oncol. 2021 07; 15(7):1747-1749.
Score: 0.277
-
The National Clinical Trials Network and the cooperative groups: The road not taken. Cancer. 2020 12 01; 126(23):5008-5013.
Score: 0.263
-
Progress in Cancer Research, Prevention, and Care. N Engl J Med. 2020 Sep 03; 383(10):897-900.
Score: 0.262
-
Closing the Rural Cancer Care Gap: Three Institutional Approaches. JCO Oncol Pract. 2020 07; 16(7):422-430.
Score: 0.258
-
Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO Oncol Pract. 2020 Jul; 16(7):417-421.
Score: 0.256
-
Talking the Talk About Tumor Genomic Testing. J Natl Cancer Inst. 2020 05 01; 112(5):436-437.
Score: 0.256
-
Reply to M. Hutton-Potts and A.M. Joshua. JCO Oncol Pract. 2020 05; 16(5):285-286.
Score: 0.254
-
Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. J Oncol Pract. 2019 11; 15(11):575-583.
Score: 0.243
-
State of Cancer Care in America: Reflections on an Inaugural Year. J Oncol Pract. 2019 04; 15(4):163-165.
Score: 0.236
-
Implementing Precision Medicine in Community-Based Oncology Programs: Three Models. J Oncol Pract. 2019 06; 15(6):325-329.
Score: 0.236
-
Accelerating anticancer drug development - opportunities and trade-offs. Nat Rev Clin Oncol. 2018 12; 15(12):777-786.
Score: 0.232
-
A New Look at the State of Cancer Care in America. J Oncol Pract. 2018 07; 14(7):397-399.
Score: 0.225
-
Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs? JAMA Oncol. 2018 03 01; 4(3):333-334.
Score: 0.220
-
The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018 03; 15(3):183-192.
Score: 0.217
-
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016 08 20; 34(24):2925-34.
Score: 0.195
-
Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20.
Score: 0.184
-
Improving evidence developed from population-level experience with targeted agents. Clin Pharmacol Ther. 2015 May; 97(5):478-87.
Score: 0.180
-
Innovative clinical trials for development of personalized cancer medicine. Mol Oncol. 2015 May; 9(5):933-4.
Score: 0.179
-
Moving from evaluation to value in cancer care. Clin Cancer Res. 2015 Mar 01; 21(5):947-9.
Score: 0.174
-
ASCO's initiative to define value in cancer care. Am J Manag Care. 2014 Aug; 20(11 Spec No.):E1.
Score: 0.172
-
Drivers of change in cancer care. J Oncol Pract. 2014 Sep; 10(5):315-6.
Score: 0.171
-
Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ. J Clin Oncol. 2014 Aug 01; 32(22):2373-9.
Score: 0.170
-
Implementing personalized cancer care. Nat Rev Clin Oncol. 2014 07; 11(7):432-8.
Score: 0.168
-
Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014; 61-9.
Score: 0.165
-
Publicly funded clinical trials and the future of cancer care. Oncologist. 2013; 18(2):232-8.
Score: 0.155
-
Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book. 2013; 118-25.
Score: 0.154
-
Personalized cancer medicine - a strategy to counteract an increasing cancer challenge. Mol Oncol. 2012 Apr; 6(2):109-10.
Score: 0.146
-
Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol. 2011 Dec 06; 9(4):208-14.
Score: 0.143
-
Using patient-initiated study participation in the development of evidence for personalized cancer therapy. Clin Cancer Res. 2011 Nov 01; 17(21):6651-7.
Score: 0.142
-
Update in hematology and oncology: evidence published in 2010. Ann Intern Med. 2011 Apr 05; 154(7):487-94.
Score: 0.136
-
Tumor heterogeneity as the foundation of personalized cancer treatment. Semin Oncol. 2011 Apr; 38(2):171-2.
Score: 0.136
-
Accrual to cancer clinical trials in the era of molecular medicine. Sci Transl Med. 2011 Mar 23; 3(75):75cm9.
Score: 0.136
-
Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol. 2010 Dec 01; 28(34):5046-53.
Score: 0.132
-
Personalized medicine in oncology: the future is now. Nat Rev Drug Discov. 2010 05; 9(5):363-6.
Score: 0.128
-
Commentary: tackling the challenges of developing targeted therapies for cancer. Oncologist. 2010; 15(5):484-7.
Score: 0.125
-
Data submission standards and evidence requirements. Oncologist. 2010; 15(5):488-91.
Score: 0.125
-
Translating the cancer genome into clinically useful tools and strategies. Dis Model Mech. 2009 Sep-Oct; 2(9-10):426-9.
Score: 0.122
-
Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol. 2009 Aug 10; 27(23):3725-30.
Score: 0.121
-
Introduction: contributions of the cooperative groups. Semin Oncol. 2008 Oct; 35(5):459.
Score: 0.115
-
The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). Clin Cancer Res. 2008 Sep 15; 14(18):5685-91.
Score: 0.114
-
How not to treat cancer. Lancet Oncol. 2008 Jun; 9(6):504-5.
Score: 0.112
-
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol. 2008 May 20; 26(15):2562-7.
Score: 0.111
-
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008 Mar 10; 26(8):1371-8.
Score: 0.109
-
The role of cooperative groups in cancer clinical trials. Cancer Treat Res. 2007; 132:111-29.
Score: 0.102
-
A concise history of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3553s-5s.
Score: 0.098
-
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s.
Score: 0.098
-
3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice. Expert Rev Mol Diagn. 2004 Jul; 4(4):431-3.
Score: 0.085
-
Drug development for major chronic health conditions-aligning with growing public health needs: Proceedings from a multistakeholder think tank. Am Heart J. 2024 Apr; 270:23-43.
Score: 0.083
-
Are targeted therapies really targeted? Clin Adv Hematol Oncol. 2003 Dec; 1(12):722-3.
Score: 0.082
-
Health Data Sharing Perspectives of Patients Receiving Care in CancerLinQ-Participating Oncology Practices. JCO Oncol Pract. 2023 08; 19(8):626-636.
Score: 0.079
-
End points in cancer clinical trials and the drug approval process. Clin Cancer Res. 2002 Apr; 8(4):935-8.
Score: 0.073
-
Use of Biosimilar Medications in Oncology. JCO Oncol Pract. 2022 Mar; 18(3):177-186.
Score: 0.072
-
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
Score: 0.072
-
Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncol Pract. 2022 04; 18(4):e426-e441.
Score: 0.071
-
The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 10; 15(10):2507-2543.
Score: 0.070
-
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. J Clin Oncol. 2021 04 01; 39(10):1165-1184.
Score: 0.067
-
Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. JCO Oncol Pract. 2021 01; 17(1):41-51.
Score: 0.067
-
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. J Clin Oncol. 2021 01 10; 39(2):155-169.
Score: 0.067
-
The International Collaboration for Cancer Classification and Research. Int J Cancer. 2021 02 01; 148(3):560-571.
Score: 0.066
-
Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. JCO Glob Oncol. 2020 Sep; 6:1461-1471.
Score: 0.065
-
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31.
Score: 0.065
-
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2020 04 01; 38(10):1081.
Score: 0.063
-
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2020 03; 25(3):e405-e411.
Score: 0.062
-
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 10; 574(7776):127-131.
Score: 0.061
-
Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology. Oncologist. 2019 10; 24(10):1287-1290.
Score: 0.061
-
Challenges and approaches to implementing master/basket trials in oncology. Blood Adv. 2019 07 23; 3(14):2237-2243.
Score: 0.061
-
The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019 05 17; 7(1):129.
Score: 0.060
-
Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise. J Clin Oncol. 2019 07 10; 37(20):1690-1694.
Score: 0.060
-
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758.
Score: 0.060
-
Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2019 04 01; 37(10):834-849.
Score: 0.059
-
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. J Clin Oncol. 2019 02 01; 37(4):336-349.
Score: 0.058
-
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. J Clin Oncol. 2019 01 01; 37(1):72-80.
Score: 0.058
-
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108.
Score: 0.058
-
Biochemical and clinical pharmacology of 5-fluorouracil. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):13-8.
Score: 0.057
-
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7.
Score: 0.055
-
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch Pathol Lab Med. 2018 10; 142(10):1242-1253.
Score: 0.055
-
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018 06 01; 36(16):1631-1641.
Score: 0.055
-
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044.
Score: 0.055
-
Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. Cell. 2017 Nov 16; 171(5):982-986.
Score: 0.054
-
Global Challenges for Cancer Imaging. J Glob Oncol. 2018 09; 4:1-10.
Score: 0.053
-
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367.
Score: 0.051
-
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1452-1459.
Score: 0.050
-
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20; 34(9):987-1011.
Score: 0.048
-
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol. 1995 Sep; 13(9):2230-7.
Score: 0.046
-
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25.
Score: 0.046
-
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015 Aug 10; 33(23):2563-77.
Score: 0.046
-
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug; 33(4):901-10.
Score: 0.045
-
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8.
Score: 0.045
-
Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology. Cancer Epidemiol Biomarkers Prev. 2015 Mar; 24(3):484-9.
Score: 0.045
-
Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst. 2015 Apr; 107(4).
Score: 0.045
-
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
Score: 0.044
-
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol. 1994 Dec; 12(12):2743-50.
Score: 0.044
-
Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014 Aug 20; 32(24):2587-94.
Score: 0.043
-
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
Score: 0.043
-
Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother Pharmacol. 1994; 34(6):509-14.
Score: 0.041
-
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst. 1993 Aug 18; 85(16):1319-26.
Score: 0.040
-
Breaking a vicious cycle. Sci Transl Med. 2013 Jul 31; 5(196):196cm6.
Score: 0.040
-
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
Score: 0.039
-
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. Cancer Res. 1993 Mar 15; 53(6):1293-6.
Score: 0.039
-
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol. 2013 Mar 20; 31(9):1134-9.
Score: 0.039
-
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993; 31(4):283-8.
Score: 0.038
-
Prospects for fertility after cancer chemotherapy. Semin Oncol. 1992 Oct; 19(5):597-604.
Score: 0.038
-
Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst. 2012 Apr 18; 104(8):581-9.
Score: 0.036
-
Development and use of integral assays in clinical trials. Clin Cancer Res. 2012 Mar 15; 18(6):1540-6.
Score: 0.036
-
Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5.
Score: 0.036
-
Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011 Nov-Dec; 61(6):365-81.
Score: 0.035
-
WIN Consortium--challenges and advances. Nat Rev Clin Oncol. 2011 Mar; 8(3):133-4.
Score: 0.034
-
The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5.
Score: 0.034
-
An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov. 2011 02; 10(2):79-80.
Score: 0.034
-
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study. Cancer Chemother Pharmacol. 1991; 28(1):69-73.
Score: 0.034
-
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
Score: 0.033
-
Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med. 2010 Apr 21; 2(28):28cm13.
Score: 0.032
-
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010 Mar 01; 16(5):1384-90.
Score: 0.032
-
Ovarian function following radiation and chemotherapy for cancer. Semin Oncol. 1989 Oct; 16(5):425-36.
Score: 0.031
-
Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. Semin Oncol. 2008 Oct; 35(5):470-83.
Score: 0.029
-
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2008 Jan 10; 26(2):313-25.
Score: 0.027
-
Clinical implications of tumor heterogeneity. Haematol Blood Transfus. 1987; 31:278-82.
Score: 0.025
-
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2007 Jan 01; 25(1):146-62.
Score: 0.025
-
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol. 2006 Oct 01; 24(28):4553-7.
Score: 0.025
-
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer. Cancer Res. 1986 Aug; 46(8):4184-8.
Score: 0.025
-
Evaluation of cognition in cancer patients: special focus on the elderly. Crit Rev Oncol Hematol. 2006 Dec; 60(3):242-55.
Score: 0.025
-
Tumor cell heterogeneity: implications for clinical practice. Semin Oncol. 1985 Sep; 12(3):203-6.
Score: 0.023
-
Cytarabine-cis-platin interactions in patients with advanced cancer. Semin Oncol. 1985 Jun; 12(2 Suppl 3):171-6.
Score: 0.023
-
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005 Apr 15; 11(8):2785-808.
Score: 0.023
-
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005 Jun; 16(6):958-65.
Score: 0.023
-
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.
Score: 0.022
-
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502.
Score: 0.022
-
Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer. Cancer Treat Rep. 1984 Sep; 68(9):1097-102.
Score: 0.022
-
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8.
Score: 0.021
-
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res. 2004 Jun 01; 10(11):3881-4.
Score: 0.021
-
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7.
Score: 0.020
-
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
Score: 0.019
-
Tumor markers as clinical cancer tests--are we there yet? Semin Oncol. 2002 Jun; 29(3):211-2.
Score: 0.018
-
Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. Clin Cancer Res. 2002 May; 8(5):943-8.
Score: 0.018
-
Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans. Cancer Res. 1982 Apr; 42(4):1582-6.
Score: 0.018
-
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
Score: 0.018
-
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90.
Score: 0.017
-
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol. 2001 Mar 01; 19(5):1476-84.
Score: 0.017
-
Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980 Jul; 93(1):109-14.
Score: 0.016
-
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul; 9(7):1635-49.
Score: 0.016
-
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. J Clin Oncol. 1998 Oct; 16(10):3302-9.
Score: 0.014
-
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998 May; 16(5):1811-9.
Score: 0.014
-
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7.
Score: 0.014
-
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule. Ann Oncol. 1997 Aug; 8(8):807-9.
Score: 0.013
-
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32.
Score: 0.013
-
Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era. Stem Cells. 1996 Jan; 14(1):29-32.
Score: 0.012
-
Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994 Oct 01; 74(7):1965-73.
Score: 0.011
-
A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994 Jul 01; 74(1):168-73.
Score: 0.011
-
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst. 1994 Mar 02; 86(5):368-72.
Score: 0.010
-
Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8.
Score: 0.010
-
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study. Cancer Chemother Pharmacol. 1993; 32(5):347-52.
Score: 0.010
-
Antifolates: the next generation. Semin Oncol. 1992 Dec; 19(6):707-19.
Score: 0.010
-
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol. 1991 Aug; 9(8):1480-6.
Score: 0.009
-
Pharmacodynamics in cancer therapy. J Clin Oncol. 1990 Oct; 8(10):1739-53.
Score: 0.008
-
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6.
Score: 0.007
-
High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987 Dec; 5(12):2017-31.
Score: 0.007
-
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb; 33(1):15-49.
Score: 0.006
-
Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65.
Score: 0.005
-
Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol. 1982 Mar; 9(1):75-83.
Score: 0.005
-
Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979 Jun; 90(6):929-31.
Score: 0.004
-
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10.
Score: 0.003
-
Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther. 1993 Oct; 54(4):421-9.
Score: 0.003
-
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1527-31.
Score: 0.001